Biocon’s Lower-priced Herceptin Biosimilar Ready To Roll But Roche Has Questions
This article was originally published in PharmAsia News
Executive Summary
On the face of it, Biocon’s trastuzumab seems not to offer a sharp price differential over Roche’s Herceptin, but the Indian company has come up with a strategy of smaller doses of 150 mg against Roche’s 440 mg dosage. Roche questioned the approval process for the metastatic breast cancer drug and called for data.